|
End-of-day quote
Taipei Exchange
19/08/2026
|
5-day change | 1st Jan Change | ||
| 939.00 TWD | +4.92% |
|
0.00% | +136.52% |
| 08-14 | Lin BioScience, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 04-28 | Lin BioScience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| Market Cap | 77.77B 2.46B 2.12B 1.99B 1.81B 3.41B 235B 3.44B 23.56B 9.2B 118B 9.23B 9.03B 394B | P/E 2024 |
-14.5x | P/E 2025 | -23.9x |
|---|---|---|---|---|---|
| Enterprise Value | 61.5B 1.94B 1.68B 1.57B 1.44B 2.7B 185B 2.72B 18.63B 7.28B 93.68B 7.3B 7.14B 311B | EV / Sales 2024 |
-
| EV / Sales 2025 | - |
| Free-Float |
100% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | +4.92% | ||
| Current month | +37.89% | ||
| 1 month | +47.18% | ||
| 3 months | +152.08% | ||
| 6 months | +129.87% | ||
| Current year | +136.52% |
| 1 month | 520 |  | 969 |
| Current year | 331 | | 969 |
| 1 year | 149 | | 969 |
| 3 years | 70 | | 969 |
| 5 years | 70 | | 969 |
| 10 years | 27 | | 969 |
| Manager | Title | Age | Since |
|---|---|---|---|
Cheng Chi Wang
CEO | Chief Executive Officer | - | 31/05/2016 |
Wan Shan Chen
DFI | Director of Finance/CFO | 40 | 24/07/2022 |
Hung Wei Chen
COO | Chief Operating Officer | 45 | 31/07/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Yue Hsin Lin
CHM | Chairman | 48 | 12/10/2016 |
Cheng Chi Wang
BRD | Director/Board Member | - | 26/06/2024 |
Hui Chun Wang
BRD | Director/Board Member | 80 | 26/09/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.92% | 0.00% | +517.76% | +633.59% | 2.46B | |
| -0.13% | -6.44% | +60.47% | +112.05% | 1,047B | |
| +0.85% | -0.81% | +52.77% | +63.15% | 646B | |
| -1.03% | -3.58% | +22.87% | +73.29% | 451B | |
| -1.46% | -4.50% | +37.43% | +38.41% | 355B | |
| -0.72% | -2.89% | +21.86% | +36.79% | 291B | |
| -1.19% | -2.21% | +1.35% | +12.29% | 252B | |
| -1.05% | -1.57% | +51.40% | +68.55% | 234B | |
| +0.08% | -1.78% | -17.64% | -54.29% | 203B | |
| -2.14% | -0.30% | +29.42% | +89.10% | 181B | |
| Average | -0.19% | -1.75% | +77.77% | +107.29% | 366.17B | |
| Weighted average by Cap. | -0.46% | -3.45% | +38.98% | +65.89% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | - |
| Net income | -744M -23.53M -20.29M -19.02M -17.37M -32.67M -2.24B -32.93M -225M -88.03M -1.13B -88.34M -86.42M -3.77B | -1.36B -43.09M -37.15M -34.83M -31.8M -59.83M -4.11B -60.3M -413M -161M -2.08B -162M -158M -6.9B |
| Net Debt | -5.17B -164M -141M -132M -121M -227M -15.6B -229M -1.57B -612M -7.88B -614M -601M -26.18B | -16.27B -514M -444M -416M -380M -714M -49.06B -720M -4.93B -1.92B -24.78B -1.93B -1.89B -82.33B |
Employees
-
Sector
Pharmaceuticals
Calendar
- Stock Market
- Stocks
- 6696 Stock
Select your edition
All financial news and data tailored to specific country editions
